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Summary 22 
Reverse genetics systems allow artificial generation of non-segmented and segmented 23 
negative-sense RNA viruses, like influenza viruses, entirely from cloned cDNA. Since the 24 
introduction of reverse genetics systems over a decade ago, the ability to generate ‘designer’ 25 
influenza viruses in the laboratory has advanced both basic and applied research, providing a 26 
powerful tool to investigate and characterize host-pathogen interactions and advance the 27 
development of novel therapeutic strategies. The list of applications for reverse genetics has 28 
expanded vastly in recent years. In this review, we discuss the development and implications 29 
of this technique, including the recent controversy surrounding the generation of a 30 
transmissible H5N1 influenza virus. We will focus on research involving the identification of 31 
viral protein function, development of live-attenuated influenza virus vaccines, host-pathogen 32 
interactions, immunity, and the generation of recombinant influenza virus vaccine vectors for 33 
the prevention and treatment of infectious diseases and cancer.  34 
 35 
Abbreviations used: CEFs, chicken embryonic fibroblasts; Gal, galactose; HPAI, highly 36 
pathogenic avian influenza; IRF3, IFN regulator factor 3; LAIV, live attenuated influenza 37 
vaccines; LPAI, low pathogenic avian influenza; PI3K, phosphatidylinositol-3 kinase; pol, 38 
polymerase; RBS, receptor binding site; RIG-I, retinoic acid-inducible gene I; SA, sialic acid; 39 
S-OIV, swine-origin influenza virus  40 
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Influenza A viruses 41 
Influenza A virus outbreaks are an annual, ongoing public health concern that place a great 42 
social and economic burden on society. Influenza virus infection is currently the leading 43 
cause of combined morbidity and mortality in the world, causing 250,000-500,000 deaths 44 
worldwide per year (Ref. 1). In the event of a pandemic influenza outbreak, these numbers 45 
can rise exponentially. A recent study indicated that the total economic costs associated with 46 
annual influenza epidemics were $29 billion in the US alone (Ref. 2).  In light of this, rapid 47 
and cost-effective production of effective vaccines targeting seasonal influenza or emerging 48 
influenza virus outbreaks is essential. Moreover, development of effective vaccines and 49 
disease prevention depend on profound knowledge of the virus itself. Reverse genetics has 50 
been exploited extensively to dissect the roles of influenza virus gene segments in disease 51 
pathogenicity, host-pathogen interactions and to develop new vaccine strategies.  52 
Influenza A belongs to the Orthomyxoviridae family of RNA viruses. The influenza A 53 
genome is divided into eight separate segments of single-stranded negative-sense RNA, 54 
which express at least 11 functional proteins: polymerase basic (PB) 2, PB1, PB1-F2, 55 
nucleoprotein (NP), hemagglutinin (HA), neuraminidase (NA), matrix (M) 1, M2, 56 
polymerase acidic (PA), non-structural protein (NS) 1, and nuclear export protein (NEP; 57 
previously known as NS2) (Ref. 3), although a 12th has recently been described and is 58 
currently being characterized (Ref. 4).  PB2, PB1 and PA form part of the RNA-dependent 59 
RNA polymerase complex, required for the synthesis of viral mRNA and viral replication 60 
(Ref. 3). PB1-F2 is thought to enhance virus-induced apoptosis and is translated from an 61 
alternative open reading frame overlapping the PB1 open reading frame (Ref. 5). HA is a 62 
surface glycoprotein responsible for attachment to host cells via surface sialic acids receptors, 63 
and NA cleaves cell surface sialic acids, releasing newly packaged virus from host cells. 64 
Individual vRNAs are bound by NP, which then interacts with the viral polymerase to form 65 
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the viral ribonucleoprotein (vRNP) complex triggering the initiation of viral RNA 66 
transcription and replication (Ref. 6). The matrix structural protein M1 is required for vRNP 67 
export to the cytosol (Ref. 7) and the ion channel protein M2 is required for virus entry and 68 
the production of infectious viral particles (Ref. 3, 8). NS1 and NEP proteins are encoded by 69 
gene segment 8 again through alternative splicing. The major role of NS1 protein is the 70 
suppression of host innate type I interferon (IFN) responses (Ref. 9). NEP is an adaptor 71 
protein that mediates the export of viral RNPs from the cell nucleus for virus assembly (Ref. 72 
3). Reverse genetics has been used to incorporate changes in the majority of the 73 
aforementioned gene segments to address questions about protein function and pathogenicity, 74 
the findings of which will be discussed further in this review. 75 
 76 
Introduction to reverse genetics systems 77 
Reverse genetics is the process of generating live viruses entirely from cloned cDNA (Ref. 78 
10). This approach has simplified the manipulation of the virus genome, allowing not only 79 
the introduction of point mutations, but the generation of reassortant viruses through the 80 
replacement of virus gene segments from different influenza virus strains or subtypes. This 81 
has enabled the delineation of protein function and the contribution each protein has made to 82 
virulence and pathogenicity, as well as the generation and development of influenza virus 83 
vaccines (Ref. 11). Furthermore, reverse genetics has also been utilized to develop influenza 84 
virus-based gene delivery systems (Ref. 12, 13).  85 
Reverse genetics systems were first established in 1978 with the generation of the non-86 
segmented positive-stranded RNA virus coliphage, Qβ (Ref. 14). This was achieved through 87 
the conversion of its viral RNA genome into double-stranded cDNA using reverse 88 
transcription. The cDNA was then cloned into a plasmid for transfection into Escherichia coli 89 
to produce phage Qβ (Ref. 14). These early studies laid the foundation for the generation of 90 
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more complex virus systems containing segmented negative-sense genomes (e.g. influenza 91 
virus) (Ref. 10). Progress towards the rescue of segmented negative-sense RNA viruses was 92 
slow and technically difficult. In contrast to the non-segmented positive-stranded RNA 93 
viruses, the genome of the negative-stranded RNA viruses is non-infectious. The two major 94 
factors contributing to these difficulties were (i) that initial viral RNA transcription and 95 
replication relied on the presence of endogenous viral RNA polymerase, and (ii) that viral 96 
genomic RNA required nucleoprotein to form a ribonucleoprotein (RNP) complex (Ref. 15). 97 
The first functional influenza RNP complex was generated in vitro in 1989 in the presence of 98 
purified NP and polymerase proteins (Ref. 16). Additional systems were established in 99 
subsequent years, based on a similar technique, to generate a recombinant influenza A virus 100 
that expressed a foreign gene from the NS gene segment (Ref. 17). Progress towards the 101 
generation of negative-stranded RNA viruses entirely from cloned cDNA gained momentum 102 
with the production of a single negative-stranded Rabies virus in 1994 (Ref. 18), followed by 103 
generation and rescue of a segmented (three RNA segments) negative-stranded Bunyamwera 104 
bunyavirus in 1996 (Ref. 19).  105 
It was not until 1999 that an influenza virus was generated entirely from cloned cDNA 106 
using reverse genetics (Ref. 20). To generate and rescue this viable influenza virus, a total of 107 
12 plasmids were initially required; eight plasmids encoding the eight viral RNAs (vRNAs) 108 
(PB2, PB1, PA, NP, HA, NA, M, NS) (Ref. 21) in combination with four plasmids that 109 
facilitated the production of polymerase complex proteins, PB2, PB1, PA, and NP (Ref. 20). 110 
In the year 2000, a more efficient reverse genetics system was developed using only eight 111 
plasmids (Ref. 22) (Fig. 1A). In this modified system, viral cDNA was inserted between a 112 
human pol I promoter and a mouse pol I terminator, driving the synthesis of negative-sense 113 
vRNAs (Ref. 22). The pol I transcription cassette was flanked by a human pol II promoter 114 
and a bovine polyadenylation signal from which mRNAs were transcribed and translated into 115 
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viral proteins (Ref. 22). This enabled negative-sense vRNAs and positive-sense mRNAs 116 
encoding viral proteins to be synthesized from the same cDNA template (Ref. 22). This 117 
technological breakthrough simplified and streamlined the rescue of influenza viruses and 118 
made reverse genetics a mainstream procedure in many influenza laboratories. 119 
The reduction in the number of plasmids required for virus rescue increased the 120 
transfection efficiency of mammalian cells, resulting in higher virus yields (Ref. 22, 23). To 121 
this end, a three-plasmid system has been developed to further improve efficiency and yield 122 
(Ref. 23) (Fig. 1B). Briefly, each of the influenza virus cDNAs were flanked by the human 123 
pol I promoter and the mouse pol I terminator to form a RNA pol I transcription cassette. The 124 
eight transcription cassettes were then cloned into one plasmid. The other two plasmids 125 
encoded the viral polymerases PB2, PB1 and PA or NP, respectively, with the cDNA flanked 126 
by a pol II promoter and a polyadenylation sequence (Ref. 23). The use of this 3 plasmid 127 
system resulted in higher transfection efficiency and virus yields in both Vero and HEK293T 128 
cells when compared with other pre-existing reverse genetics systems (Ref. 23).  129 
 More recently, a one-plasmid reverse genetics system was developed (Ref. 24) (Fig. 1C). 130 
cDNAs encoding PB2, PB1, PA and NP were first inserted between a pol I promoter-131 
terminator and a pol II promoter-terminator. The pol II promoter was omitted from the 132 
cassette containing HA, NA, M or NS. All 8 cassettes were then ligated to form a single 133 
plasmid. Virus yields generated using the one-plasmid system were comparable to the eight-134 
plasmid system in chicken embryonic fibroblasts (CEFs), and were improved substantially 135 
with co-culture of CEFs and MDCK cells (Ref. 24). One of the key features of this system is 136 
the use of unique restriction sites between cassettes, allowing replacement of viral genes with 137 
circulating seasonal genes for vaccine production (Ref. 24). Moreover, it provides a useful 138 
research tool for the study virulence determinants through the generation of recombinant 139 
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viruses. Despite these incremental improvements in technology, the 8-plasmid system 140 
remains the workhorse in the field. 141 
 142 
Current applications for influenza virus reverse genetics systems 143 
(i) Use of influenza reverse genetics to study host range 144 
Influenza viruses infect host cells by binding to sialic acid moieties via HA, followed by 145 
receptor-mediated endocytosis and fusion of the viral and endosomal membranes (for review, 146 
see (Ref. 25)). Avian influenza viruses bind to cell-surface receptors whose sugars terminate 147 
in sialic acid (SA)-α2,3-galactose ((SA)α2,3-Gal), which is abundant on avian intestinal 148 
epithelia (Ref. 26). Human-adapted influenza viruses bind to SAα2,6-Gal-linked receptors 149 
expressed for the most part on the surface of airway epithelia (Ref. 26). It should also be 150 
noted that there is emerging evidence to suggest that avian influenza viruses can infect host 151 
cells in the absence of canonical sugar moieties (Ref. 27, 28). The phrase ‘antigenic drift’ 152 
describes the accumulation of mutations (predominantly in HA and to a lesser extent in NA), 153 
resulting in the emergence of antigenic variants of influenza virus and is responsible for our 154 
annual seasonal outbreaks (Ref. 29, 30). The antigenic sites where changes occur have been 155 
mapped to the globular head of HA in an area surrounding the receptor-binding pocket (Ref. 156 
29) or the substrate-binding site of NA (Ref. 31). Mutations at the receptor-binding site can 157 
influence the host range of influenza viruses. It is thought that the avian origin 1918 158 
pandemic virus acquired its ability to infect humans through mutations in HA (Ref. 32). Use 159 
of reverse genetics to analyse human and avian host range (for H2 and H3 viruses) has 160 
demonstrated that Q226L and G228S substitutions change the binding preference for these 161 
viruses from human SAα2,6-Gal receptor to avian SAα2,3-Gal receptor (Ref. 33). Other 162 
studies have shown that for H1 viruses, E190D and D225G substitutions facilitate 163 
preferential binding to the human SAα2,6-Gal receptors (Ref. 33).  164 
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(ii) Use of reverse genetics to produce inactivated and live influenza vaccines 165 
Vaccines (live and inactivated) are currently available to control influenza virus infection 166 
and provide between 80-100% protection in children and adults under the age of 65 (Ref. 34, 167 
35). There are currently two vaccine formulations available to protect humans against 168 
seasonal influenza; inactivated vaccines and live attenuated influenza vaccines (LAIV) (Ref. 169 
36). Both vaccines are generated using reverse genetics systems, incorporating the HA and 170 
NA gene segments from circulating strains in combination with six backbone gene segments 171 
to produce a product using egg-based technology (Ref. 36). There are some limitations with 172 
these vaccines, including poor efficacy in the elderly (Ref. 37). In addition, as the inactivated 173 
vaccine is administrated intramuscularly, it does not induce a strong mucosal immune 174 
response of the upper respiratory tract as seen during natural infection (Ref. 38). Reverse 175 
genetics has been used to generate an effective commercially available LAIV (FluMist®) (Ref. 176 
39) that is delivered as a nasal spray and has been licensed for use in the USA since 2003 177 
(Ref. 40) and in the European Union since 2011 as Fluenz™ (Ref. 41).  178 
 179 
(iii) Use of reverse genetics to develop universal influenza vaccines 180 
The 2009 pandemic caused by the swine origin influenza virus (S-OIV) H1N1 and the 181 
ongoing pandemic threat associated with the highly pathogenic avian influenza (HPAI) H5N1 182 
subtype highlight the urgent need for the development of a universal influenza vaccine with a 183 
capacity to induce cross protective cellular immunity (Ref. 42). Current research has focused 184 
on conserved sequences in structural proteins, such as the extracellular domain of the matrix 185 
protein 2 (M2e) and NP (Ref. 43). A recent study analyzing memory CD4+ and CD8+ T cells 186 
from individuals in the UK and Viet Nam demonstrated cross-reactive immune responses 187 
targeting internal proteins, M1 and NP following A/Vietnam/CL26/2005 (H5N1) and A/New 188 
York/232/2004 (H3N2) infection (Ref. 44). Moreover, mice primed with two viruses, 189 
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A/Puerto Rico/8/1934 H1N1 (PR8) and A/Hong Kong/X31 H3N2 (X31), showed 190 
significantly improved protection (90% in primed mice vs 10% in un-primed mice) following 191 
challenge with HPAI A/Vietnam/1203/2004 H5N1 that was attributed to the cross-protective 192 
cellular immunity (Ref. 45). Other studies have shown that reverse genetics can be used to 193 
generate recombinant A/WSN/33 (WSN) H1N1 viruses expressing previously defined human 194 
influenza T cell epitopes (M1, NS1, NP, PB1 and PA epitopes) in the NP (NPmix) or 195 
together with conserved sequences in the N-terminus of NA and C-terminus of HA from 196 
H5N1 virus (NA-HA) (Ref. 46). Vaccinated BALB/c mice primed with the two 197 
corresponding recombinant NP DNA constructs showed increased influenza virus-specific 198 
CD4+ and CD8+ T cell responses in splenocytes stimulated with NP peptide (TYQRTRALV), 199 
which clearly correlated with decreased viral load in the lungs (Ref. 46).  200 
Despite these advances, a major limitation of current influenza vaccination strategies is the 201 
long lead-time (up to six months) required to produce vaccine (Ref. 47) and the possibility of 202 
vaccine shortages in the event of a pandemic (Ref. 47). In view of these limitations, a rapid, 203 
cost-effective, and consistent production pipeline is essential. Established reverse genetics 204 
systems, along with well-defined egg-based technology, and emerging in vitro approved cell 205 
lines for seasonal vaccine production are the foundation of future pandemic preparedness. 206 
The effectiveness of this reverse genetics technology was demonstrated by the production of 207 
a safe, high-yielding human influenza vaccine in Vero cells in response to HPAI H5N1 virus 208 
in a period of 4 weeks in 2003 (Ref. 11). The polybasic amino acids from the H5N1 HA 209 
cleavage site were removed to attenuate the virus and a reassortant vaccine virus strain was 210 
rescued using a modified HA (H5) and NA (N1) from A/Hong Kong/491/97 H5N1 virus, 211 
along with standard backbone internal gene segments from PR8 H1N1 virus (Ref. 48).   212 
 213 
 214 
10 
 
(iv) Use of reverse genetics to elucidate determinants of viral pathogenicity 215 
Effective prevention and control of influenza viruses depends on a detailed understanding 216 
of the virus at the molecular level. The ongoing advances in our understanding of molecular 217 
mechanisms driving influenza pathogenicity have been made possible with the establishment 218 
and refinement of reverse genetics technology (Ref. 49, 50). Below we highlight and discuss 219 
critical examples noted in the literature and present the impact on pathogenesis and virulence.   220 
 221 
The PB2 protein 222 
The viral RNP complex consisting of PB2, PB1, PA and NP plays a key role in adaptation 223 
and virulence of avian influenza viruses (Ref. 50, 51). The PB2 protein is responsible for the 224 
initiation of viral mRNA transcription and RNA polymerase activity within infected cells 225 
(Ref. 3). Several amino acids within PB2, such as 701 and 627, have been implicated in 226 
mammalian host range adaptation (Ref. 52, 53) and virulence (Ref. 49, 54). A single mutation 227 
in the PB2 subunit at position 701 from aspartic acid (D) (consensus residue in avian viruses) 228 
to asparagine (N) (D701N) in avian H5N1 and H7N1 subtypes enable the viruses to infect 229 
mice (Ref. 53, 55) and humans (Ref. 56). In addition, the PB2 D701N has been found in 230 
human isolates of HPAI H5N1 virus, as well as in avian-like swine virus (Ref. 53).  231 
Another amino acid residue in the PB2 segment that has come under intense scrutiny is 232 
amino acid 627. In general, avian influenza viruses usually encode a glutamic acid (E) at 233 
position 627 (E627) in PB2, whereas human viruses possess a lysine (K627). Sequence 234 
analyses and comparisons between two well studied H5N1 human isolates, A/Hong 235 
Kong/483/97 (HK483-lethal in mice) and A/Hong Kong/486/97 (HK486-non-lethal in mice), 236 
uncovered eight amino acid differences, including K in HK483 vs E in HK486 at position 627 237 
(Ref. 49). HK483 influenza viruses with a K627E substitution in PB2 (generated with reverse 238 
genetics) displayed attenuated virulence in mice (Ref. 49). In contrast, HK486 influenza 239 
11 
 
viruses with an E627K substitution in PB2 became increasingly adapted to mouse cell lines 240 
when compared to wild type virus (Ref. 54) and were lethal in mice (Ref. 49, 54).  241 
 242 
The PB1-F2 protein 243 
Segment 2 of the influenza genome encodes two proteins, PB1 and PB1-F2, from different 244 
open reading frames. PB1, as part of the polymerase complex, is involved in viral mRNA 245 
synthesis and elongation (Ref. 57). Use of reverse genetics to generate single 1:7 gene 246 
reassortants between the 1918 Spanish pandemic strain and a seasonal human H1N1 247 
A/Texas/36/91 (1918 PB1:Tx/91) demonstrated that PB1 was a major virulence determinant 248 
in the 1918 virus by increasing replication efficiency in human airway cells and lungs of mice 249 
(Ref. 58).  250 
PB1-F2 can act as a pro-apoptotic protein sensitizing cells to apoptosis (Ref. 59) and 251 
regulate viral replication through its interaction with PB1, influencing polymerase activity 252 
(Ref. 60). The PB1-F2 sequence of the PR8 strain was compared to that of the 1918 253 
pandemic virus and the seven amino acids differences between the two were incorporated 254 
into the PR8 PB1-F2 open reading frame (R33H, G40D, R60Q, N66S, I68T, L69P, F71S, 255 
END88W) to generate a 1918-like PB1-F2 using reverse genetics (Ref. 61). The mutant 256 
virus, PR8-PB1-F2 (1918), demonstrated accelerated viral replication kinetics in vivo and 257 
resulted in higher mortality, increased incidence of pulmonary inflammation, secondary 258 
bacterial infection and mortality in mice when compared with the wild type PR8 virus (Ref. 259 
61).  260 
Sequence alignment of PB1-F2 from human isolates of the Hong Kong H5N1 outbreak 261 
(A/Hong Kong/483/1997) and the 1918 H1N1 pandemic virus revealed the presence of a 262 
serine (S) at position 66 in both the Hong Kong 1997 H5N1 virus and the 1918 H1N1 virus. 263 
LPAI/intermediate H5N1 viruses contain an N in the same position (Ref. 62). Two 264 
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recombinant WSN viruses containing a S or an N at position 66 were generated using reverse 265 
genetics to determine the impact on virulence (Ref. 62). The WSN N66S virus demonstrated 266 
increased virulence in infected mice as indicated by increased weight loss, higher virus titres 267 
in the lungs and delayed virus clearance. In contrast, a reconstructed 1918 virus with the 268 
S66N mutation showed significant attenuation (Ref. 62).  269 
 270 
The NS1 protein 271 
The NS1 protein is a recognized virulence determinant and has been shown to be involved 272 
in numerous processes associated with replication and host immunity. Firstly, it has been 273 
shown to increase NP and M1 protein expression through the stimulation of viral mRNA 274 
translation (Ref. 63). In addition, NS1 has been shown to activate the phosphatidylinositol-3 275 
kinase (PI3K)/Akt pathway to prevent virus-induced apoptosis in cells (Ref. 64). The best 276 
characterized function of NS1 is its suppression of host antiviral immune responses through 277 
its actions as a type I IFN antagonist, preventing important IFN-mediated antiviral responses. 278 
It interrupts retinoic acid-inducible gene I (RIG-I)-mediated signalling in response to viral 279 
RNA (Ref. 65, 66, 67, 68). It has been proposed that the type I IFN antagonistic action of 280 
NS1 contributed to the virulence of the 1918 “Spanish Flu” (Ref. 69). C-terminal truncations 281 
and single amino acid substitutions of the NS gene segment generated through reverse 282 
genetics have been used to identify regions that affect virulence (Ref. 9, 70). Deletion of the 283 
NS1 gene segment at position 80–84 (Ref. 71) and a D to E substitution at position 92 (D92E) 284 
(Ref. 72) were shown to be associated with increased virulence and resistance to antiviral 285 
IFNs.  286 
Further in-depth analysis of the NS1 protein identified a four amino acid peptide sequence 287 
(predominantly ESEV in avian, and RSKV in human) that forms a PDZ domain ligand (PL) 288 
(Ref. 73). PDZ domains are highly-conserved protein-protein interaction modules that bind to 289 
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PDZ domain ligands in target proteins (Ref. 74) and are involved in trafficking and assembly 290 
of signaling complexes (Ref. 74). The avian NS1 protein containing the ESEV motif bound to 291 
a wide range of human PDZ domains, whilst human NS1 protein containing the RSKV motif 292 
showed little binding (Ref. 73). Recombinant WSN viruses encoding different PL motifs, 293 
including the 1918 H1N1 virus, HPAI H5N1 virus, and seasonal human H3N2 strains, were 294 
generated using reverse genetics. Recombinant viruses containing PL motifs from HPAI 295 
H5N1 and 1918 H1N1 viruses showed increased virulence in mice, whilst deletion of the PL 296 
motif resulted in decreased virulence (Ref. 75).  297 
The NS1 protein consists of an N-terminal dsRNA-binding domain (residue 1 - 73) that is 298 
important in RIG-I inhibition and a C-terminal domain (residue 74 - 230) that coordinates 299 
interactions with host proteins and stabilizes the RNA binding domain and a NS1 tail. NS1 300 
exits as a homodimer, which is essential for dsRNA binding (Ref. 76). Binding of NS1 to 301 
dsRNA blocks the dsRNA-activated antiviral protein kinase, PKR, dampening the host 302 
antiviral response (Ref. 77). A tryptophan at position 187 (W187) is critical for this process 303 
(Ref. 78). A recombinant PR8 virus with a single mutation of tryptophan at position187 to 304 
arginine (rPR8 NS1-W187R) was generated using reverse genetics to disrupt dimerisation 305 
(Ref. 79). rPR8 NS1-W187R showed decreased dsRNA-binding ability that correlated with 306 
poor inhibition of the IFN-β promoter. Moreover, mice infected with rPR8 NS1-W187R 307 
displayed improved survival rates with lower virus titres in the lung compared to controls. 308 
 309 
The HA protein 310 
The ability of influenza virus to bind and infect cells to gain access to cell machinery 311 
requires cleavage of the HA protein (HA0) by cellular proteases to form two subunits, HA1 312 
and HA2 (Ref. 29). The availability and location of these cellular proteases influences the site 313 
of virus replication. For example, influenza virus replication in mammals is generally 314 
14 
 
restricted to the respiratory tract because this is where serine proteases that cleave HA are 315 
produced (Ref. 80). However, the HA of HPAI H5 and H7 viruses can be cleaved by 316 
ubiquitously expressed proteases due to the presence of the multiple basic amino acid motif  317 
(R-X-K/R-R) at the HA1-HA2 cleavage site (Ref. 81). Reverse genetics has been utilized to 318 
generate mutant viruses with altered HA cleavage sites to correlate HA cleavability with 319 
virulence (Ref. 81). Results suggest that the length of the cleavage site (P8-Q7-R6-R5-R4-K3-320 
K2-R1) as well as the presence of basic amino acid (K) at position 2 and 3 are important for 321 
optimal cleavage (Ref. 81).  322 
The HA receptor binding site of influenza virus is located on each HA monomer as part of 323 
a trimeric HA globular head (Ref. 25). A key amino acid on the surface of the HA1, tyrosine 324 
(Y) 161, has been shown to be essential for HA receptor recognition and virus entry (Ref. 82). 325 
An Y161A mutation introduced into A/Hong Kong/213/03 H5N1 virus using reverse genetics 326 
resulted in a change of tropism from avian species to mammals. In addition, in vitro infection 327 
studies with this H5N1 Y161A recombinant virus resulted in impaired growth in MDCK cells 328 
(Ref. 82). Detailed analyses of two 1918 pandemic strains have identified a single amino acid 329 
difference at position 225 of HA (Ref. 83). The strain with a D at position 225 shows higher 330 
binding affinity to human SAα2,6Gal when compared to avian SAα2,3Gal (Ref. 83). 331 
Moreover, replacement of D to E using reverse genetics (as per most LPAI avian viruses) at 332 
position 190 (D190E) reduced binding affinity for the human SAα2,6Gal receptor (Ref. 83). 333 
Another key residue identified within the H1 HA receptor-binding site is residue 227 (Ref. 84, 334 
85). While human H1N1 viruses, including the 2009 pandemic H1N1 virus strain, encode 335 
E227, swine or swine-origin influenza viruses generally contain an alanine (A) in this 336 
position (Ref. 84). Introduction of an E227A mutation or expression of swine HA in the 2009 337 
H1N1 virus via reverse genetics altered cell tropism and resulted in poorer fitness in primary 338 
human airway epithelial cells (Ref. 84).  339 
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(v) Utilizing reverse genetics to dissect influenza-specific immunity 340 
The innate immune response against influenza virus infection is characterized by the 341 
infiltration of neutrophils and monocytes into the lung. The release of pro-inflammatory 342 
cytokines and chemokines by alveolar macrophages, lung epithelial cells and dendritic cells 343 
(DC) leads to the induction of adaptive immunity characterized by the generation of 344 
influenza-specific neutralizing antibodies by B cells and the activation and expansion of 345 
virus-specific CD4+ and CD8+ T cells that assist in clearing virus (Ref. 86). Reverse genetics 346 
can be used as a valuable tool to study how influenza virus manipulates host cellular and 347 
immune environments to ensure optimal propagation and prolonged survival. 348 
 349 
Innate immunity 350 
Toll-like receptors (TLRs) expressed by DCs, natural killer (NK) cells and macrophages 351 
play a critical role in regulating innate immune responses following influenza virus infection 352 
(Ref. 87, 88). TLR3, 7, 8 and 9 expressed in the endosomal membranes recognize nucleic 353 
acid and viral components upon infection. This triggers the activation of intracellular 354 
signaling pathways and leads to the induction of antiviral cytokine production (e.g. type I 355 
IFNs) by virus-infected cells (Ref. 87, 89, 90). Type I IFNs bind to cell surface receptors, 356 
activating the JAK-STAT, TLR and retinoic acid-inducible gene I (RIG-I)-like receptor (RLR) 357 
signaling pathways, resulting in the augmentation of interferon-stimulated/responsive genes 358 
and induction of pro-inflammatory responses (Ref. 89, 90). Importantly, IFNs induce 359 
maturation of DCs, contributing to the augmentation of the antiviral state, including 360 
activation of T cell immunity (Ref. 90). As a consequence, viruses have developed various 361 
mechanisms to evade protective type I IFN defense mechanisms. The influenza NS1 protein 362 
plays a major role in evading host immune responses as mentioned earlier in this review (Ref. 363 
91, 92). Influenza virus reverse genetics systems have been used to carefully dissect these 364 
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host-pathogen interactions. In vitro infection of human peripheral blood DCs with a 365 
recombinant PR8 virus incorporating a NS1 gene deletion resulted in suboptimal maturation, 366 
activation and migration of mature myeloid DCs. This correlated with reduced cytokine gene 367 
expression and anti-viral function (including T cell activation) compared to wild type virus as 368 
a result of weak stimulatory signals (Ref. 91). Similar results were also observed with a 369 
seasonal influenza virus A/Tx/91 and its A/Tx/91 NS1-deletion counterpart (Ref. 92). 370 
Furthermore, the NS1 C-terminus has been shown to interrupt RIG-I signaling by inhibiting 371 
IFN regulator factor 3 (IRF3) phosphorylation and activation, preventing transcription of type 372 
I IFNs and other IFN-induced genes (Ref. 92). When reverse genetics was used to delete the 373 
NS1 C-terminal region involved in this interaction, the newly generated recombinant virus 374 
replicated poorly in primary human bronchial epithelial cells (Ref. 92). 375 
 376 
Reverse genetics and influenza-specific CD8
+
 T cell immunity 377 
CD8+ T cell responses are stimulated by the presentation of viral peptides bound to MHC 378 
class I glycoproteins to T cell receptors (TCR) on the T cell surface (Ref. 93). The design and 379 
development of a cross-reactive universal CD8+ T cell-based influenza virus vaccine 380 
targeting the highly conserved internal proteins can only be achieved if our underlying 381 
knowledge of influenza-specific CD8+ T cell-mediated immunity is clearly defined. Within 382 
this context, consideration must also be given to the application of immune pressure in order 383 
to avoid the emergence of mutations in the virus that could lead to CTL immune escape (Ref. 384 
94, 95, 96). Importantly, the magnitude of CD8+ T cell responses of different specificities 385 
following infection is not uniform. The way in which these specificities are ordered is 386 
referred to as an immunodominance hierarchy (Ref. 97). Understanding the significance of 387 
immunodominance hierarchies is critical for improving our understanding of cellular 388 
immunity and informing future vaccine design and development. In the C57BL/6J (B6, H2b) 389 
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mouse model of infection, two immundominant influenza A virus-specific CD8+ T cell 390 
epitopes, nucleoprotein (NP366-374) and acid polymerase (PA224-233), are presented via the 391 
H2Db MHC class I molecule (DbNP366 and D
bPA224, respectively) (Ref. 98, 99). The 392 
asparagine anchor residue at position 5 in these well-defined epitopes is responsible for high 393 
affinity binding to H2Db (Ref. 100, 101). Analyses of primary infection in studies conducted 394 
by the Doherty group have demonstrated co-dominance between the two specificities. 395 
However, following secondary infection, the DbNP366-specific response is clearly 396 
immunodominant (increased by at least 14-fold in the spleen) when compared to the DbPA224 397 
response (Ref. 99). To understand the significance of this immunodominance hierarchy and 398 
its underlying mechanisms, recombinant viruses were generated using reverse genetics to 399 
substitute the N at position 5 for both epitopes to glutamine (Q), thereby abrogating 400 
presentation and ensuring loss of specificity (Ref. 102, 103, 104). This loss of specificity for 401 
DbNP366 and D
bPA224 allowed compensatory expansion of the normally subdominant 402 
KbPB1703 CD8
+ T cell population after secondary challenge (Ref. 102). Further detailed 403 
analyses revealed additional compensatory expansion of other minor epitopes (KbNS2114 and 404 
the KbM1128) (Ref. 103). These experiments clearly demonstrated the plasticity of 405 
subdominant CD8+ T cell populations and gave us important insights into their ability to 406 
contribute to immunity when required in different/unique circumstances. The role of 407 
protective antibody also became more prominent following secondary infection when 408 
recombinant viruses expressing both NP366 and PA224 N-Q mutations were used to infect 409 
mice (Ref. 102). The Doherty group has also used reverse genetics to equilibrate expression 410 
of DbNP366 and D
bPA224 epitopes to examine the role of antigen presentation in establishing 411 
immunodominance hierarchies by inserting the aforementioned epitopes within the NA stalk 412 
(NANP and NAPA, respectively).  Endogenous expression was disabled using N-Q mutations 413 
(Ref. 104) and results suggested that the development of CD8+ T cell responses to a certain 414 
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MHC class I/epitope complex following primary infection was determined not only by the 415 
number of naïve CD8+ T cell precursors available, but also by the type of antigen presenting 416 
cells (APC) expressing the epitope (Ref. 104). The recall response in these experiments was 417 
influenced by the number of CD8+ memory T cells present following primary infection and 418 
the level of epitope presentation (Ref. 104).  419 
The significance of T cell immunodominance was  further investigated through the 420 
introduction of the exogenous OVA257-264 immunodominant peptide (SIINFEKL; presented 421 
by H2Kb, Kb-OVA257) into the NA stalk of PR8 and X31 influenza viruses (PR8-OVA and 422 
HK-OVA) using reverse genetics (Ref. 105). The presence of a normally immunodominant 423 
exogenous antigen did not extensively alter normal endogenous influenza-specific responses 424 
upon infection. The magnitude of the Kb-OVA257-specific CD8
+ T cell response was 425 
equivalent to that of the DbNP366-specific CD8
+ T cell population after primary infection (Ref. 426 
105). Two other specificities, DbPA224 and K
bPB1703, were slightly reduced after primary and 427 
secondary infection. However, the magnitude of overall CD8+ T cell response was similar in 428 
the presence or absence of KbOVA257 (Ref. 105). Co-dominance of the D
bNP366 and 429 
KbOVA257 CD8+ T cell responses was only disrupted when mice were administered virus 430 
intraperitoneally, resulting in abortive infection. As a result, the DbNP366 CD8
+ T cell 431 
response was observed to be immunodominant over the exogenous KbOVA257 CD8
+ T cell 432 
population in a process influenced by viral protein abundance (Ref. 105).  433 
Another factor thought to play a key role in immunodominance is engagement of the 434 
MHC-peptide complex with the TCR (Ref. 106). Numerous recombinant X31 viruses 435 
containing single amino acid substitutions along the NP366-374 peptide, A1S2N3E4N5M6E7T8M9, 436 
have been used to study this further (Ref. 106). Analysis of IFN-γ production through 437 
intracellular cytokine staining demonstrated that M6 is critical for TCR recognition of 438 
DbNP366. The methionine to alanine substitution (M6A) was shown not to affect overall virus 439 
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fitness or NP peptide expression and presentation in mutant viruses. As a result, the 440 
DbNPM6A CD8+ T cell population detected following infection of mice was 441 
immunodominant (just as the DbNP366 CD8
+ T cell population in wild type virus) and showed 442 
little cross-reactivity, but did display weaker TCR avidity (Ref. 106). This was validated 443 
when the crystal structure for both interactions was solved, showing similar binding patterns 444 
for NP366 and NP366M6A to the H2-D
b antigen-binding cleft. The lack of CD8+ T cell cross-445 
reactivity was attributed to altered interactions at the binding cleft as a result of the M6A 446 
mutation (Ref. 106). These studies have highlighted the fact that pre-immunization against 447 
mutant influenza viruses may in fact elicit new CD8+ T cell memory populations to assist in 448 
protection against emerging mutant strains. 449 
The majority of studies dissecting influenza-specific CD8+ T cell immunity using reverse 450 
genetics have directly or indirectly involved members of the Doherty laboratory. Other 451 
research groups have also taken advantage of this system to generate influenza viruses 452 
expressing exogenous T cell epitopes of interests to study pathogen-specific responses and 453 
pathogen-pathogen interactions. A recent study using a recombinant PR8 virus expressing the 454 
CD8 T cell epitope of Mycobacterium tuberculosis, MPT64, demonstrated that co-infection 455 
with Mycobacterium bovis bacille Calmette-Guérin (BCG) resulted in exacerbated disease 456 
and delayed mycobacterial clearance in lungs influenced perhaps by lower MHC Class I and 457 
II expression on DCs and impaired activation of pathogen-specific CD4 and CD8 T cells (Ref. 458 
107). Further examples include the use of recombinant X31 and PR8 influenza A viruses 459 
expressing multiple SIV CD8 T cell epitopes to induce simian immunodeficiency virus 460 
(SIV)- and influenza-specific responses in non-human primates or the use of a recombinant 461 
WSN influenza virus expressing the gB CD8 T cell epitope of HSV-1 to characterise the 462 
expression of CD94/NKG2 receptors on virus-specific CD8 T cells (Ref. 108, 109, 110). 463 
 464 
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Reverse genetics and influenza-specific B cell immunity 465 
Influenza-specific B cell responses are critical for protection following primary and 466 
secondary influenza virus infection (Ref. 111). Influenza-specific antibodies are rapidly 467 
induced against several influenza viral proteins (Ref. 112). Antibody responses targeting the 468 
HA glycoprotein, are often stronger and have significant virus neutralizing capacity (Ref. 469 
113). In addition to the aforementioned vaccine strategies that aim to elicit influenza virus-470 
specific CD8 T cell responses, cross-reactive neutralizing antibodies that can target diverse 471 
viral clades are being developed as an alternative treatment option (Ref. 113). Current 472 
research on cross-reactive neutralizing antibodies has focused on identifying antibodies that 473 
target conserved HA stalk domains (Ref. 113, 114). Importantly, reverse genetics has been 474 
used to alter glycosylation sites on the surface of the HA. Work by Job et al. has identified a 475 
glycosylation site at Asn136 on the HA of the 2009 Pandemic influenza A (H1N1) virus that 476 
was associated with resistance to neutralizing antibodies and higher virus titers in mice (Ref. 477 
115). Although reverse genetics has not been extensively used to study influenza-specific B 478 
cell immunity or the development of neutralizing antibodies, a recombinant WSN influenza 479 
virus expressing a immunodominant B cell epitope of the β-amyloid peptide (Aβ42) was used 480 
to confer protection against Aβ42-mediated neurotoxicity, a neuropathological feature of 481 
Alzheimer’s Disease (Ref. 116). Moreover, novel cross-reactive antibody responses have 482 
been generated following insertion of the OVA 323–339 CD4 T cell epitope (OT-II) into the HA 483 
using influenza reverse genetics (Ref. 117). These studies demonstrate the potential value of 484 
using reverse genetics to dissect B cell immunity and antibody production and its use should 485 
be investigated further in the future.  486 
 487 
 488 
 489 
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(vi) Influenza A viruses as vectors for vaccine development 490 
Advances in technology, such as reverse genetics, have enabled the genetic modification 491 
of negative-strand RNA viruses to express T cell epitopes and genes. The availability of live 492 
attenuated influenza virus strains, such as influenza A/Ann Arbor/6/60 (H2N2) and B/Ann 493 
Arbor/1/66 cold-adapted viruses, for seasonal influenza vaccination (Ref. 118, 119, 120, 121) 494 
also provides an established safety profile for future use in humans. Furthermore, reverse 495 
genetic techniques have been optimised over the last decade, allowing production of high titre 496 
recombinant viruses (Ref. 20, 23, 24).  497 
Influenza viruses have been used as vectors to treat cancer (Ref. 122, 123, 124) and 498 
infectious diseases, such as AIDS (Ref. 125, 126, 127), malaria (Ref. 12, 128), and 499 
pseudomonas aeruginosa (Ref. 129, 130). Influenza A virus vectors have been engineered to 500 
express a β-galactosidase (β-gal) CD8+ T cell epitope in the HA or NA protein for the 501 
recognition of β-gal expressing tumours (Ref. 122). Mice vaccinated with the recombinant 502 
influenza virus expressing the β-gal CD8+ T cell epitope (MINIGAL, NAGAL and BHAGAL) 503 
stimulated specific cytotoxic CD8+ T cells that targeted tumour cells expressing β-gal, and 504 
reduced lung metastases and increased survival was observed in vaccinated mice with 505 
established experimental tumours (Ref. 122, 123). Regression (> 6 months) was also 506 
observed in mice with lower initial tumour burdens (Ref. 123). 507 
Development of a safe and effective HIV vaccine remains one of the scientific 508 
community’s great scientific challenges. High genetic diversity (Ref. 131, 132) and a lack of 509 
knowledge regarding immune correlates has impeded progress (Ref. 133). A recently 510 
completed Phase III trial (RV144) conducted in Thailand tested a combination prime-double 511 
boost vaccination regimen using a live recombinant canarypox vector and gp120 protein for 512 
boosting (Ref. 134). The trial demonstrated 31% efficacy, suggesting for the first time that a 513 
preventive HIV vaccine was achievable using a live virus-based delivery system (Ref. 134).   514 
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It is evident that cellular immunity, especially virus-specific CD8+ T cells, are involved in 515 
the control of HIV (Ref. 133). Influenza viruses replicate in respiratory organs, but are 516 
capable of inducing mucosal immune responses at distal mucosa, including the urogenital 517 
where exposure to HIV occurs (Ref. 126, 127). In addition, vaccination usually produces 518 
long-lasting, virus-specific humoral responses, such as secretory IgA, which is the major 519 
humoral defence mechanism at mucosal surfaces (Ref. 135). Recombinant influenza viruses 520 
have been used in mice to stimulate HIV envelope-specific cellular and humoral immunity at 521 
mucosal sites (Ref. 136, 137). In recent work, recombinant H1N1 or H3N2 influenza virus 522 
vectors expressing SIV CD8+ T cell epitopes in the NA stalk have been evaluated for their 523 
ability to stimulate mucosal T cell immunity and efficacy in a rhesus macaque model (Ref. 524 
13). These viruses were generated using reverse genetics and elicited SIV-specific and 525 
influenza specific CD8+ T cell responses in animals following a prime-boost protocol via the 526 
respiratory tract. Vaccination of SIV-exposed macaques resulted in a significant expansion of 527 
SIV-specific CD8+ T cell in the peripheral blood (approximately 14%). Despite the fact that 528 
SIV challenge of influenza virus-SIV vaccinated resulted in a strong recall of SIV-Gag 529 
specific CD8+ T cell responses, SIV vireamia and CD4+ T cell counts were not altered 530 
compared to controls and the vaccination regimen was thought to have contributed to the 531 
early establishment of CTL escape mutants. Use of influenza virus vectors expressing 532 
multiple HIV antigens to elicit broader HIV-specific CD8+ T cell responses may be required 533 
to minimize the impact of CTL escape (Ref. 138).  534 
 535 
(vii) Utilizing reverse genetics to dissect the mechanisms of influenza virus drug 536 
resistance 537 
Current antiviral drugs that are FDA approved for clinical use against influenza in the 538 
United States can be classified into two categories: (i) viral M2 ion channel blockers (the 539 
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adamantine drugs, amantadine and rimantadine) and (ii) the NA inhibitors (NAIs) (zanamivir 540 
(Relenza®) and oseltamivir (Tamiflu®)) (www.cdc.gov). The former target the 541 
transmembrane domain of the M2 protein and are effective against influenza A viruses (Ref. 542 
139), whilst the latter bind to the NA catalytic site and are effective for both influenza A and 543 
B viruses due to the high degree of conservation of the residues (Ref. 140). Influenza viral 544 
RNA polymerases have poor proof-reading ability that results in high mutation rates during 545 
replication. Therefore, antiviral resistance can happen spontaneously or under selection 546 
pressure following antiviral therapy (Ref. 141). As such, widespread resistance to 547 
adamantanes and/or oseltamivir has been documented in circulating influenza A H3N2 and 548 
seasonal and pandemic H1N1 subtypes (Ref. 142). In addition, the novel H7N9 virus that 549 
recently caused an outbreak in China has been found to contain mutations that can confer 550 
resistance to both classes of antiviral agents (Ref. 143). These events highlight the urgent 551 
need to acquire a better understanding of viral resistance patterns and the characteristics of 552 
the resistant strains. Reverse genetics systems have been extensively used to generate or 553 
recapitulate mutations identified in a clinical setting (Ref. 144, 145, 146). The molecular 554 
mechanism for amantadine-resistance is relatively straightforward and has been characterized 555 
as a single mutation at S31N in the transmembrane domain of the M2 gene (Ref. 144, 147). 556 
Other M2 mutations (L26F, V27A, A30T, G34E) that have been associated with resistance to 557 
amantadine were also validated using recombinant WSN H1N1 viruses generated with 558 
reverse genetics (Ref. 144). NAI resistance is far more complex. NA mutations are found to 559 
be subtype-specific and be induced in vitro using different NAIs or observed clinically 560 
following treatment of infected individuals (Ref. 148, 149). The H274Y mutation conferring 561 
resistance is frequently described for the H1N1 subtype (Ref. 148, 149, 150), while R292K is 562 
commonly observed in the N2 and N9 subtypes (Ref. 142, 151). Unlike the M2 mutations 563 
that maintain viral fitness and infectivity, NA mutations, such as H274Y, E119G, E119V, 564 
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N294S, of the N1 and N2 subtypes show lower levels of viral fitness and virulence as 565 
demonstrated in vitro in cell culture or in mice infected with reverse genetics generated 566 
recombinant WSN viruses (Ref. 145, 146). Moreover, subsequent studies have shown that the 567 
impaired viral fitness of an E119V oseltamivir-resistant H3N2 influenza A virus recovered 568 
from an immunocompromised patient can be partially restored with the addition of a I222V 569 
mutation using reverse genetics (Ref. 152). The compensatory effects of the I222V mutation 570 
were further validated through the generation of a recombinant pandemic H1N1 virus 571 
(A/Québec/144147/09), demonstrating that the I222V mutation can also restore the fitness of 572 
the H274Y mutant and promote its resistance to both oseltamivir and peramivir (Ref. 146). It 573 
is important to note that a single I222V mutation alone only confers minor resistance to 574 
oseltamivir (Ref. 146). Knowledge of antiviral drug-resistant phenotypes is important for 575 
monitoring the emergence and spread of resistance and forms an integral part of pandemic 576 
planning. 577 
 578 
FUTURE PERSPECTIVES 579 
The ability to generate and manipulate live recombinant influenza viruses using reverse 580 
genetics systems continues to provide insights into the mechanisms involved in virus 581 
infection on host immunity. One example is a recent study in which a GFP reporter gene was 582 
expressed from the NS segment of PR8 (NS1-GFP virus), that has enabled localization and 583 
replication studies of the virus in vivo (Ref. 153). The recombinant NS1-GFP influenza virus 584 
is pathogenic in mice and capable of replicating, although less virulent than un-manipulated 585 
wild type PR8. This valuable tool can now be used to study movement of virus through tissue 586 
following infection (Ref. 54, 153, 154) and cell populations infected by GFP-tagged viruses 587 
can be isolated by flow cytometry.  588 
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Since the first human infection of HPAI H5N1 influenza virus in 1997 (Ref. 155), 648 589 
laboratory confirmed human cases have been identified with a mortality rate of nearly 60% 590 
(http://www.who.int/influenza/human_animal_interface). To date, zoonotic transmission of 591 
HPAI H5N1 has been largely associated with close contact with infected poultry. Given the 592 
high mutation rates of influenza viruses, it remains a significant concern that HPAI H5N1 593 
viruses could acquire the ability to transmit between humans. In recent years, scientists have 594 
been focusing on identifying factors that influence the transmissibility of HPAI H5N1 viruses. 595 
Two independent groups recently generated H5N1 mutant viruses using reverse genetics that 596 
were readily transmitted via airborne particles in ferrets (Ref. 156), and identified key amino 597 
acid residues that facilitate transmission of H5N1 in mammals (Ref. 157, 158). Knowledge of 598 
these residues is important for surveillance and implementation of pandemic prevention 599 
strategies. 600 
Some of the major issues facing clinicians and scientists in the influenza field include (but 601 
are not limited to); emergence of novel epidemic or pandemic virus strains; virus resistance to 602 
multiple anti-viral drugs; improvement of vaccine production (including use of enhanced cell 603 
lines that improve rescue of viruses or inhibit antiviral immunity) (Ref. 159, 160); 604 
development of universal vaccines (T cell or antibody-based); improvement of vaccine 605 
efficacy in the elderly; and finally, ethical concerns involving the use of reverse genetics to 606 
generate potentially pandemic viruses with so called ‘dual use’ potential (Ref. 161, 162).   607 
Reverse genetics has played a critical role in improving our understanding of influenza 608 
virus pathogenesis and immunity and will continue to do so in the future. This was clearly 609 
evidenced recently through the rapid identification and characterization of the circulating 610 
H7N9 virus subtype in China (Ref. 163, 164) and will certainly help answer questions arising 611 
from the identification of novel virus strains such as the H17N10 virus isolated from bats in 612 
Guatemala (Ref. 165, 166). New and exciting technological advances in influenza reverse 613 
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genetics, such as the expression of miRNAs, offers scientists opportunities to regulate virus 614 
replication and host immune responses and has implications in areas such as vaccine 615 
production (Ref. 167). In conclusion, our ability to reconstruct and manipulate the influenza 616 
virus genome using reverse genetics and the knowledge gained will undoubtedly lead to 617 
improved therapeutics and vaccines in the future.  618 
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Figure 1. Eight, two and one plasmid(s) reverse genetics systems. (a) Eight plasmids 
reverse genetics system (Ref. 22).  In each of the expression plasmid, the cDNA encoding 
one of the  eight influenza viral segments was inserted between a human pol I promoter and a 
murine pol I terminator. This pol I cassette is then flanked by the pol II promoter of the 
human cytomegalovirus and the polyadenylation signal of the gene encoding bovine growth 
hormone.  This pol I – pol II system will result in the transcription of the eight vRNAs 
through the pol I promoter using cellular pol I, and the transcription of viral mRNAs through 
pol II. vRNAs will then be translated into viral proteins. The core of the virus contains the 
vRNPs that is wrapped up around NP and joined with the viral RNA polymerase complex 
(PB1, PB2 and PA). Infectious influenza virus will be formed following assembly of vRNPs 
and proteins HA, NA, M1, M2 and NS. (b) Three plasmids reverse genetics system (Ref. 23). 
One plasmid contains cDNAs for all eight viral segments, each flanked by pol I promotor-
teminater pair; the other plasmid contain three RNA pol II transcription cassettes containing 
cDNA encoding PB2, PB1 and PA for the transcription of the three mRNAs; the third 
plasmid contains a pol II transcription unit of NP. (c) One plasmid reverse genetics system 
(Ref. 24). Expression plasmids were generated using a similar pol I – pol II system as (a). All 
eight cDNA cassettes for the eight viral segments were combined into one expression 
plasmid. Each cDNA cassette consist of the cDNA flanked by the pol I – pol II system. 
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